search
Back to results

Efficacy and Safety of Minodronate in Patients With Low Back Pain

Primary Purpose

Postmenopausal Osteoporosis

Status
Not yet recruiting
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Minodronate
Alendronate
Sponsored by
Peking University Third Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postmenopausal Osteoporosis focused on measuring minodronate, low back pain, adverse reactions, pharmacokinetic, pharmacodynamic

Eligibility Criteria

55 Years - 95 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Chinese postmenopausal patients with a diagnosis of OP; Patients with low back pain of at least 3 months and a VAS score ≥30; The value of lumbar L1-4 or total hip bone density measured by DXA is < -2.5; Serum 25-hydroxyvitamin D (25-OHD) concentration ≥20 ng/mL; Patients with full capacity for civil conduct and understanding of the research process and methods voluntarily participated in this study and signed the informed consent form. Exclusion Criteria: Patient who are allergic to minodronate, alendronate, or other bisphosphonate drug or any other component of the drug under evaluation; Patients with a diagnosis of secondary OP; The following drugs affecting bone metabolism were used before the screening: Received injections of bisphosphonate and denosumab within 3 years; Received oral bisphosphonate, parathyroid hormones or analogues, strontium, or fluoride within 6 months; Received glucocorticoids, steroids, immunosuppressants, calcitonin, calcitriol or its analogues, thiazide diuretics, and ng-acting oestrogen/progesterone replacement therapy within 3 months; Patients with a diagnosis of diseases affecting bone metabolism (e.g., osteogenesis imperfecta, malignancy, progressive diaphyseal dysplasia, Paget's disease, rheumatoid arthritis, osteosclerosis, osteoporosis with a slipped disc and spinal stenosis, and liver and kidney failure); Patients are participating or have participated in an investigational drug study within 3 months before signing the informed consent form; Patients under 75 years old with a creatinine clearance rate < 60 mL/min and those > 75 years old with a creatinine clearance rate < 45 mL/min; Serum calcium levels < 2.0 mmol/L (8 mg/dL) or > 2.7 mmol/L (11.0 mg/dL); Patients with fever, severe infection, severe trauma, or major surgery within 30 days; Patients with a QTc interval of > 480 ms; Patients are undergoing or planning to undergo invasive dental treatment; Smoking history in the past six months; Patients with a history of alcohol abuse (> 15 g of alcohol per day, equivalent to 350 mL of beer or 150 mL of wine, more than twice per week) and drug abuse; Patients with a prior history of cerebral infarction, ischaemic or haemorrhagic stroke; Patients with implants and/or fractures in the lumbar spine or hip that interfere with BMD testing; Received pain relievers (e.g., nonsteroidal anti-inflammatory drugs, central analgesics) or life interventions to relieve pain within 1 week before screening;

Sites / Locations

  • Peking University Third Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

minodronate

alendronate

Arm Description

Patients will take 1 mg of minodronate tablets orally in the morning.

Patients will be orally given 10 mg alendronate tablets daily in the morning.

Outcomes

Primary Outcome Measures

The time for a 10 point decrease in the VAS score within 24 weeks
The VAS scores were measured daily within 24 weeks. Back pain was evaluated using a 100-mm VAS score ( 0 = no pain, 100 = worst pain possible) after treatment, where the patients recorded their pain on the VAS by themselves everyday.

Secondary Outcome Measures

Concentration in plasma of minodronate and alendronate on the first day before administration
Minodronate and alendronate concentration in plasma
Concentration in plasma of minodronate and alendronate on the 8th week after administration
Minodronate and alendronate concentration in plasma
Concentration in plasma of minodronate and alendronate on the 12th week after administration
Minodronate and alendronate concentration in plasma
Concentration in plasma of minodronate and alendronate on the 24th week after administration
Minodronate and alendronate concentration in plasma
Maximum concentration of minodronate and alendronate within 24 weeks
The observed maximum concentration following administration (Cmax) in plasma after minodronate and alendronate administration.
AUC of minodronate and alendronate within 24 weeks
The area under the concentration-time curve (AUC) in plasma after minodronate and alendronate administration.
Apparent clearance of minodronate and alendronate within 24 weeks
The apparent clearance (CL/F) of minodronate and alendronate after administration.
The pharmacodynamic of minodronate and alendronate on the first day before administration
Assessment of bone mineral density at the lumbar spine, and total hip
The pharmacodynamic of minodronate and alendronate on the 12th week after administration
Assessment of bone mineral density at the lumbar spine, and total hip
The pharmacodynamic of minodronate and alendronate on the 24th week after administration
Assessment of bone mineral density at the lumbar spine, and total hip
The incidence of upper gastrointestinal symptoms
The incidence of upper gastrointestinal symptom after medication administration

Full Information

First Posted
November 18, 2022
Last Updated
December 8, 2022
Sponsor
Peking University Third Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05645289
Brief Title
Efficacy and Safety of Minodronate in Patients With Low Back Pain
Official Title
Efficacy and Safety of Minodronate in the Treatment of Postmenopausal Osteoporosis With Low Back Pain: a Single-centre and Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2023 (Anticipated)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
April 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peking University Third Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study will provide objective evidence for the efficiency and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain protocol. Furthermore, it will be helpful to evaluate the quantitative relationship between bone metabolic markers (BTM) and bone mineral density (BMD) in patients with osteoporosis under different ages.
Detailed Description
The study is a randomized, parallel controlled clinical trial in Chinese postmenopausal OP patients receiving minodronate or alendronate. Minodronate will be administered once daily for 12 weeks, and alendronate will be administered once daily for 12 weeks. This study is divided into two stages: the first stage is 12 weeks, and at the end of the first stage, the results of patients' back pain and gastrointestinal adverse reactions will be summarized; the second stage is 12 weeks, and the pharmacokinetic and pharmacodynamic characteristics of patients will be summarized at the end of the second stage. The VAS score in this study rangs from 0-100 mm. During the screening, the patient's past pain relief methods, such as pain medication or the way of life intervention will be recorded. The use of the above methods during the patients' treatment will be prohibited to prevent interference with the results of the clinical trials. During the treatment, if patients experience sudden aggravation of low back pain, the VAS score is more than 70, and the patients could not bear the pain, a rescue drug (acetaminophen) will be used uniformly to relieve the pain. Throughout the trial, a total of 5 follow-up visits will be planned. The VAS score, PK&PD sampling, BMD evaluation, and Izumo scale score will be calculated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postmenopausal Osteoporosis
Keywords
minodronate, low back pain, adverse reactions, pharmacokinetic, pharmacodynamic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
minodronate
Arm Type
Experimental
Arm Description
Patients will take 1 mg of minodronate tablets orally in the morning.
Arm Title
alendronate
Arm Type
Active Comparator
Arm Description
Patients will be orally given 10 mg alendronate tablets daily in the morning.
Intervention Type
Drug
Intervention Name(s)
Minodronate
Other Intervention Name(s)
Difumi
Intervention Description
The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
Intervention Type
Drug
Intervention Name(s)
Alendronate
Other Intervention Name(s)
Fushanmei
Intervention Description
The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
Primary Outcome Measure Information:
Title
The time for a 10 point decrease in the VAS score within 24 weeks
Description
The VAS scores were measured daily within 24 weeks. Back pain was evaluated using a 100-mm VAS score ( 0 = no pain, 100 = worst pain possible) after treatment, where the patients recorded their pain on the VAS by themselves everyday.
Time Frame
up to 24 weeks
Secondary Outcome Measure Information:
Title
Concentration in plasma of minodronate and alendronate on the first day before administration
Description
Minodronate and alendronate concentration in plasma
Time Frame
on the first day before administration
Title
Concentration in plasma of minodronate and alendronate on the 8th week after administration
Description
Minodronate and alendronate concentration in plasma
Time Frame
on the 8th week after administration
Title
Concentration in plasma of minodronate and alendronate on the 12th week after administration
Description
Minodronate and alendronate concentration in plasma
Time Frame
on the 12th week after administration
Title
Concentration in plasma of minodronate and alendronate on the 24th week after administration
Description
Minodronate and alendronate concentration in plasma
Time Frame
on the 24th week after administration
Title
Maximum concentration of minodronate and alendronate within 24 weeks
Description
The observed maximum concentration following administration (Cmax) in plasma after minodronate and alendronate administration.
Time Frame
0-24 weeks
Title
AUC of minodronate and alendronate within 24 weeks
Description
The area under the concentration-time curve (AUC) in plasma after minodronate and alendronate administration.
Time Frame
0-24 weeks
Title
Apparent clearance of minodronate and alendronate within 24 weeks
Description
The apparent clearance (CL/F) of minodronate and alendronate after administration.
Time Frame
0-24 weeks
Title
The pharmacodynamic of minodronate and alendronate on the first day before administration
Description
Assessment of bone mineral density at the lumbar spine, and total hip
Time Frame
on the first day before administration
Title
The pharmacodynamic of minodronate and alendronate on the 12th week after administration
Description
Assessment of bone mineral density at the lumbar spine, and total hip
Time Frame
on the12th week after administration
Title
The pharmacodynamic of minodronate and alendronate on the 24th week after administration
Description
Assessment of bone mineral density at the lumbar spine, and total hip
Time Frame
on the 24th week after administration
Title
The incidence of upper gastrointestinal symptoms
Description
The incidence of upper gastrointestinal symptom after medication administration
Time Frame
0-24 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chinese postmenopausal patients with a diagnosis of OP; Patients with low back pain of at least 3 months and a VAS score ≥30; The value of lumbar L1-4 or total hip bone density measured by DXA is < -2.5; Serum 25-hydroxyvitamin D (25-OHD) concentration ≥20 ng/mL; Patients with full capacity for civil conduct and understanding of the research process and methods voluntarily participated in this study and signed the informed consent form. Exclusion Criteria: Patient who are allergic to minodronate, alendronate, or other bisphosphonate drug or any other component of the drug under evaluation; Patients with a diagnosis of secondary OP; The following drugs affecting bone metabolism were used before the screening: Received injections of bisphosphonate and denosumab within 3 years; Received oral bisphosphonate, parathyroid hormones or analogues, strontium, or fluoride within 6 months; Received glucocorticoids, steroids, immunosuppressants, calcitonin, calcitriol or its analogues, thiazide diuretics, and ng-acting oestrogen/progesterone replacement therapy within 3 months; Patients with a diagnosis of diseases affecting bone metabolism (e.g., osteogenesis imperfecta, malignancy, progressive diaphyseal dysplasia, Paget's disease, rheumatoid arthritis, osteosclerosis, osteoporosis with a slipped disc and spinal stenosis, and liver and kidney failure); Patients are participating or have participated in an investigational drug study within 3 months before signing the informed consent form; Patients under 75 years old with a creatinine clearance rate < 60 mL/min and those > 75 years old with a creatinine clearance rate < 45 mL/min; Serum calcium levels < 2.0 mmol/L (8 mg/dL) or > 2.7 mmol/L (11.0 mg/dL); Patients with fever, severe infection, severe trauma, or major surgery within 30 days; Patients with a QTc interval of > 480 ms; Patients are undergoing or planning to undergo invasive dental treatment; Smoking history in the past six months; Patients with a history of alcohol abuse (> 15 g of alcohol per day, equivalent to 350 mL of beer or 150 mL of wine, more than twice per week) and drug abuse; Patients with a prior history of cerebral infarction, ischaemic or haemorrhagic stroke; Patients with implants and/or fractures in the lumbar spine or hip that interfere with BMD testing; Received pain relievers (e.g., nonsteroidal anti-inflammatory drugs, central analgesics) or life interventions to relieve pain within 1 week before screening;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Huan Wang, Ms.
Phone
18251825313
Ext
+86
Email
wh18324178960@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Chunli Song, Pro.
Email
schl@bjmu.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chunli Song, Pro.
Organizational Affiliation
Peking University Third Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University Third Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100191
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huan Wang, Ms.
Phone
18251825313
Ext
+86
Email
wh18324178960@163.com
First Name & Middle Initial & Last Name & Degree
Chunli Song, Pro.

12. IPD Sharing Statement

Citations:
PubMed Identifier
23076293
Citation
Yoshioka T, Okimoto N, Okamoto K, Sakai A. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients. J Bone Miner Metab. 2013 Mar;31(2):153-60. doi: 10.1007/s00774-012-0393-x. Epub 2012 Oct 19.
Results Reference
background

Learn more about this trial

Efficacy and Safety of Minodronate in Patients With Low Back Pain

We'll reach out to this number within 24 hrs